Molecular and Cellular Biology, November 1999, p. 7305-7313, Vol. 19, No. 11
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

andDepartment of Infectious Diseases (Virology), Imperial College School of Medicine, London W12 0NN, United Kingdom
Received 25 January 1999/Returned for modification 8 March 1999/Accepted 11 August 1999
| |
ABSTRACT |
|---|
|
|
|---|
The exquisite sensitivity of the Burkitt's lymphoma (BL)-derived
cell line Daudi to type I interferons has not previously been
explained. Here we show that expression of an Epstein-Barr virus (EBV)
transcript, designated D-HIT (Y. Gao et al., J. Virol. 71:84-94,
1997), correlates with the sensitivity of different Daudi cell isolates
(or that of other EBV-carrying cells, where known) to alpha interferon
(IFN-
). D-HIT, transcribed from a GC-rich repetitive region (IR4) of
the viral genome, is highly structured, responding to RNase digestion
in a manner akin to double-stranded RNA. Comparing EBV-carrying BL cell
lines with differing responses to IFN-
, we found the protein levels
of the dsRNA-activated kinase, PKR, to be similar, whereas the levels of the autophosphorylated active form of PKR varied in a manner that
correlated with endogenous levels of D-HIT expression. In a classical
in vitro kinase assay, addition of either poly(I)-poly(C) or an in
vitro-transcribed D-HIT homolog stimulated the autophosphorylation activity of PKR from IFN-
-treated cells in both EBV-positive and
EBV-negative B lymphocytes. By transfection experiments, these RNAs
were shown to reduce cell proliferation and to sensitize otherwise
relatively insensitive Raji cells to IFN-
. The data lead to a model
wherein the D-HIT viral RNA also serves as a possible transcriptional
activator of IFN-
or cellular genes regulated by this cytokine.
| |
INTRODUCTION |
|---|
|
|
|---|
Since the discovery that
interferons, a family of multifunctional secreted cytokines, might
block viral replication, they have been widely studied for their
ability to defend eukaryotic cells against infectious agents or to act
themselves as antitumor agents. Interferons exert their activities by
binding to cell receptors, triggering signals that result in the
altered expression of numerous cellular (or viral) genes (reviewed in
reference 39). One of the best characterized of the
interferon pathways uses a double-stranded RNA (dsRNA)-activated
protein kinase, PKR, to phosphorylate and inactivate the peptide chain
initiation factor eIF-2, blocking translation. A second pathway has an
inducible RNA endonuclease activity (RNase L) capable of cleaving
numerous cellular and viral RNAs and regulatory factors, thus
modulating the expression of interferons themselves (as reviewed in
references 13 and 33). In
addition to these well-defined interferon-associated cellular pathways,
PKR has been shown to have an effect on cellular pathways other than
those directly associated with protein synthesis, increasing the
emphasis on this function as a cell growth regulator (as discussed in
reference 25 for NF-
B and reference
37 for c-myc).
Some of the earliest studies on interferon focused on Epstein-Barr
virus (EBV)-carrying Burkitt's lymphoma (BL)-derived cell lines. It
was shown that several of these, such as the Namalwa line,
spontaneously produced alpha interferon (IFN-
) and that different
lines varied in their capacities for expressing viral functions. Cell
lines that spontaneously produced IFN-
were refractory to
superinfection with EBV, suggesting that this protein blocked cellular
susceptibility to the virus (1). Other BL-derived lines,
among them Daudi and Raji, made undetectable or very low amounts of
interferon and could be superinfected with virus or induced to express
EBV genes. Daudi cells especially proved to be remarkably sensitive to
IFN-
, 5 to 10 U/ml being sufficient to reduce viral gene expression
by 50% (as measured by endogenous early antigen expression). More than
500 U/ml was required to produce the same effect with Raji cells
(2). Daudi has since become almost axiomatically the cell
line of choice for studying mechanism(s) of action of type I
interferons, and mutants with various responses to exogenous interferon
have been generated (9, 41). In studies using Daudi cell
lines of different interferon sensitivities, the levels of expression
of the c-myc oncogene, which is translocated and deregulated
in BL cells, were found to be decreased in (sensitive) wild-type Daudi
cells upon treatment with IFN-
but to be little altered in an
(insensitive) mutant line (31). In the former, transcription
of c-myc could also be down-regulated by sodium
n-butyrate (SB), in a manner independent of
interferon-inducible RNase L (36).
Three EBV functions have been studied with regard to the sensitivity of infected cells to interferons.
(i) The EBV nuclear antigen EBNA2, a transactivator function essential
for B-cell immortalization, has been described as being at least partly
responsible for conferring resistance to the antiproliferative effect
of interferon (3). In Daudi cells, where the genome has a
deletion that removes the EBNA2 gene (20), superinfection with a virus strain expressing this protein restores resistance to
IFN-
(21). The mechanism of action of EBNA2 in this
context has not been defined. Notably, Daudi cells can also be
converted to interferon-insensitive lines in the absence of EBNA2
(9, 41).
(ii) The EBV small polymerase III-transcribed viral RNAs (the EBERs),
as well as adenovirus VA RNAs, have been shown to interact with PKR to
limit the activity of the kinase as an inhibitor of protein synthesis
(40). Where Daudi cells are concerned, it seems unlikely
that the EBER-PKR interaction can explain the differential sensitivities to IFN-
among the various wild-type and mutant lines,
however, since in all of them the EBERs are expressed at very high,
probably supersaturating, levels for PKR.
(iii) Transcripts from the major EBV genome internal repeat (IR1, or BamHI W fragment) have been suggested to act as regulators of one or other of the interferon pathways, since in vitro they can compete with EBERs for binding to PKR (10); they also regulate kinase activity, although, unlike the EBERs, they do not block its activation by dsRNA. Again, without further evidence, it seems difficult to invoke this RNA as accounting for the observed differential responses to interferon, since all EBV-positive cells, regardless of their interferon sensitivities, carry multiple (10 to 14) copies of the viral IR1 gene.
If EBV itself is involved in regulating the cellular response to
interferon, it seemed to us that a viral function(s) other than those
described above was playing a role in the differing responses observed
among the various natural or mutant BL-derived lines. Here, we describe
a viral transcript in Daudi cells, designated D-HIT (Daudi highly
inducible transcript), that is a potential candidate for this activity.
D-HIT, present in low but detectable levels in wild-type Daudi cells,
is transcribed from a region of the EBV genome carrying the GC-rich
repetitive sequence, IR4. It is polyadenylated and predicted to have
considerable secondary structure (12). D-HIT, or its viral
homolog in other EBV-carrying cells, is differentially expressed in the
various cell lines, the highest levels of transcription being found in
IFN-
-sensitive Daudi cells (as summarized in Table
1). Since this transcript might represent
an endogenous double-stranded modulator of interferon pathways, we
studied its potential for explaining the differential sensitivity to
IFN-
among Daudi isolates and other EBV-carrying cells.
|
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials.
IFN-
(interferon alfa-2a; Roferon-A) was
purchased from Roche Products Ltd., and poly(I)-poly(C) was purchased
from Pharmacia Biotech, UK. No length information is provided with the
latter product since the two strands are synthesized independently and then annealed together. It is believed to be primarily double stranded
(information from the manufacturer).
Cell lines and cultivation.
Daudi, Namalwa, P3HR1, and Raji
are EBV-positive BL-derived cell lines, and Ramos is an EBV-negative BL
line. NAD-C15, a human lymphoblastoid line, and M-ABA, a marmoset
lymphoblastoid line, were established with EBV from nasopharyngeal
carcinomas. Daudi/ATCC (CCL 213) cells were obtained from the American
Type Culture Collection, and Daudi/ICRF and an interferon-resistant
mutant (100K) were from I. M. Kerr (Imperial Cancer Research Fund,
London, United Kingdom). All B-cell lines were grown in RPMI 1640 medium (Gibco) supplemented with 10% (vol/vol) fetal calf serum under
standard conditions and were passaged twice weekly. Actively dividing
cells were treated, at densities of 5 × 105 cells/ml,
in growth medium with 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma) at 20 ng/ml for 72 h, and/or SB (BDH) at 3 mM for 72 h or with IFN-
at 500 U/ml for 20 h, unless otherwise stated.
Cell growth assays for IFN-
sensitivity.
BL-derived Daudi
or Daudi-mutated (100K) and Raji cell lines were maintained by
adjusting the cell concentration to 2 × 105 living
cells/ml in fresh growth medium in the continuous presence of different
concentrations of interferon. The number of living cells at 7-day
intervals was determined by the trypan blue exclusion assay. Each
culture was monitored for 4 weeks.
RNA isolation and Northern blotting. RNA was isolated from the B-cell lines by the guanidinium-cesium chloride method and probed essentially as described elsewhere (12, 22). Polyadenylated RNA was selected by using two sequential oligo(dT) mRNA purification columns (Pharmacia). An actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeper gene probe was routinely used to confirm that comparable quantities of RNAs had been loaded onto gels.
Digestion of RNA with RNases. Total RNAs from TPA- and SB-induced Daudi/ATCC cells were treated with RNase A (0.1 mg/ml; Sigma) in a digestion buffer composed of 25 mM Tris HCl (pH 7.2), 10 mM MgCl2, and 200 mM NaCl at 20 or 37°C and with RNase V1 (20 U/ml; Pharmacia) in the digestion buffer at 20°C, respectively, over time and then assayed by Northern blot analysis. Blots were hybridized with the BamHI Ia region of the viral genome (4, 17) or with probes for rRNAs.
In vitro synthesis of the Raji D-HIT homolog. In the absence of cloned fragments from Daudi cells, the D-HIT homolog was synthesized in vitro with a DNA template from Raji cells. A 3.4-kb DNA fragment encompassing the IR4 region, between nucleotide positions 905 and 4340 (22, 23a) was cleaved from the EBV BamHI-Ia clone (4, 17) with restriction enzymes XbaI and SmaI, subcloned into Bluescript (Stratagene), and then transcribed in vitro from a T3 promoter in the vector, using a standard protocol (38).
Transfection of cells with the D-HIT homolog or poly(I)-poly(C)
RNAs.
Confluent Raji, Ramos, and Daudi/ICRF cells were harvested,
washed with ice-cold phosphate-buffered saline, pelleted, and resuspended in serum-free RPMI 1640 medium plus antibiotics, to give a
final concentration of 2 × 105 to 3 × 105 cells/ml. Cell suspensions (300 µl) were placed into
24-well plates and incubated for 2 to 3 h to allow the cells to
adhere to the plastic. In a series of control experiments, we assessed the usefulness of two reagents, Effectene and SuperFect, as
transfection agents that could be used in small volumes for introducing
RNA into lymphocytes without undue toxicity, using conditions
recommended by the manufacturer (Qiagen). In our hands, Effectene was
the better of the two reagents. Two sets of conditions, optimized for
Raji cells, were eventually established. After removal of medium, cells
were transfected with either 5 µl of Effectene plus 6.4 µl of
Enhancer in 400 µl of EC buffer (conditions 1) or 10 µl of
Effectene plus 6.4 µl of Enhancer in 400 µl of EC buffer (conditions 2), with added dsRNA [either 16 or 4 µl of
poly(I)-poly(C) or 4 µl of purified IR4 RNA, both at 1 µg/µl],
according to the manufacturer's instructions. After 2 h of
incubation, 800 µl of complete tissue culture medium was added to
each well to allow the cells to grow and detach from the dish.
Following overnight growth, 200-µl aliquots of cells from each of the
24 wells were transferred to 96-well dishes, to provide equal numbers
of cells for 4 new wells. In total, 48 wells of each of the three cell lines were used in subsequent experiments aimed at measuring DNA replication and cell survival, as previously described (5). To 32 of these wells, IFN-
(4 µl) was added to produce a
concentration of 104 U/ml. Cells were left overnight, and
to 20 of the wells, [3H]thymidine (8.0 µCi/well) was
added. Control cells were either untransfected, transfected in the
absence of dsRNA, or transfected in its presence with tritiated
thymidine in the absence of IFN-
. After 5 days, tritium uptake was
measured in aliquots of cells as described previously (5).
Fresh medium (100 µl) was added to the other wells, and cells from
these wells were stained with trypan blue 7 days later. Live (bright
colorless) cells were counted on a hemacytometer and compared with dead
or dying (blue) cells in control cells receiving IFN-
, with or
without Effectene, and in cells transfected with RNA and treated with
IFN-
. Three separate counts were made for each experiment in
duplicate wells (six for a single set of conditions); when on occasion
difficulties in counting were experienced due to cell clustering,
further counts (up to eight) were made.
Protein extraction, Western blotting, and immunoprobing. Proteins from B-cell lines were extracted, their concentrations were determined by the bicinchoninic acid assay (Sigma), and they were separated on a sodium dodecyl sulfate-10% polyacrylamide gel. Products were electrotransferred onto nitrocellulose membranes and then probed with an anti-PKR kinase monoclonal antibody (71/10; Ribogene) as described elsewhere (18, 26). Immunocomplexes were detected by incubation with a horseradish peroxidase-conjugated secondary antibody (Dako) and visualized by enhanced chemiluminescence (ECL reagent; Amersham).
Protein kinase assay.
PKR was immunoprecipitated by
incubating protein extracts from IFN-
treated or untreated B-cell
lines with monoclonal antibody 71/10 followed by complex binding to
protein G-Sepharose (Pharmacia). Washed immunoprecipitates were
resuspended in a buffer containing 10 mM Tris-HCl (pH 7.6), 100 mM KCl,
2.5 mM MgCl2, 2.5 mM MnCl2, and 10 mM
2-mercaptoethanol and incubated with 2 mM [
-32P]ATP
(50 Ci/mmol) at 30°C for 20 min, with or without added synthetic poly(I)-poly(C) (0.8 µg/ml; Pharmacia) dsRNA, or the EBV D-HIT homolog (0.8 µg or 8.0 µg/ml) from Raji cells. Phosphorylated PKR
was separated by polyacrylamide gel electrophoresis, and products were
identified by autoradiography.
| |
RESULTS |
|---|
|
|
|---|
Structure of D-HIT RNA. Our previous studies showed that Daudi/ATCC cells endogenously expressed low levels of a transcript (called D-HIT) from a repetitive region of the EBV genome. Induction of these cells (with SB and TPA) led to levels of the RNA that, alongside rRNAs, could even be seen by ethidium bromide staining of gels during separations of total cellular RNA (12). Experiments aimed at assessing translation of D-HIT were carried out with poly(A)+-selected RNA, purified on sucrose gradients, in an in vitro rabbit reticulocyte translation system. Here, not only was there no protein product observed, but control mRNA (supplied by the manufacturer), when mixed with D-HIT RNA from Daudi cells, was also not translated (data not shown). These findings, reminiscent of results obtained when double-stranded or otherwise highly structured RNA is used in in vitro translation systems (19), coupled with sequence analysis (12), prompted us to examine the sensitivity of D-HIT to enzymes specific for single-stranded (RNase A) or double-stranded (RNase V1) RNase. The results (Fig. 1A) show that RNase A activity at 20°C (or even at 37°C [data not shown]) has only a slight effect on D-HIT over time, whereas the dsRNA-specific RNase V1 cleaves it almost instantaneously; the opposite result was obtained on digestion of ribosomal (18S) RNA (Fig. 1B).
|
86.5 kcal/mol (12).
Comparison of interferon sensitivities and levels of D-HIT
expression in Daudi cell isolates and other B lymphocytes.
The
structural evidence raised the question whether D-HIT, acting as a
dsRNA-like RNA, might account for the observed enhanced sensitivity of
Daudi cells, compared with some other EBV-carrying cells, to IFN-
(1, 2). To explore this question, two separate Daudi
isolates (Daudi/ATCC and Daudi/ICRF), an interferon-insensitive mutant
of Daudi (100K), and Raji cells were assessed for their differential
responses to various doses of IFN-
and then compared with their
corresponding levels of D-HIT. In the interferon sensitivity studies,
considerable variation to IFN-
was observed among the parental and
mutant Daudi cell lines; Daudi/ATCC cells, for example, were found to
be intermediate in response between Daudi/ICRF and its resistant
mutant, 100K, the latter being more like Raji cells in its behavior.
Plotting cell survival versus time as a function of IFN-
concentration (in units/milliliter), with Daudi/ICRF, 50% cell
survival (or death) was achieved after 4 days with 10 U and after about
10 days with 1 U. By comparison with Daudi/ATCC cells, neither of these
interferon concentrations results in 50% cell death, even after 28 days. With Daudi/ATCC cells, the 50% figure was reached after 6 days
with 104 U and at about 12 days with 103 U. Direct comparisons are complicated by the very nature of the considerable differences in sensitivities and also the fact that the
response was not a linear one. With Raji and 100K cells, 50% cell
death was not achieved at the maximum IFN-
concentrations (104 U) even after 28 days. In the case of Raji, at 7 days,
about 90% of the cells were still alive; at 14 days, this figure had dropped to about 70%, where it remained more or less steady up to 28 days. With 100K, 10% cell death (with 104 U) was observed
only after 21 days and may not be wholly attributable to the action of
interferon. Figure 2 gives the overall
pattern of cell responsiveness of Daudi/ATCC over the range of IFN-
concentrations employed in these studies (1 to 104 U).
Superimposed on this pattern, for comparison purposes, are curves
obtained for Daudi/ICRF (at 1 and 10 U), Raji (at 104 U),
and P3HR1 (at 102 U), where the data are taken from the
literature (2).
|
D-HIT, IFN-
, and interferon-inducible cellular transcriptional
expression in Daudi/ATCC and other EBV-positive B lymphocytes.
Northern blot analyses of D-HIT expression are shown in Fig.
3 and 4.
Endogenous levels of expression of D-HIT, compared with levels induced
in Daudi/ATCC cells with either TPA or SB, are shown in Fig. 4A. Both
chemical agents induce RNA expression, with the highest levels (track
3) produced by the action of SB. Elevated D-HIT expression was also
observed when cells were grown in IFN-
(102 U/ml, for 3 days); levels of the transcript were slightly lower, however, than that
observed in the TPA induction experiments (data not shown). To compare
with these data, we investigated the RNA levels of dsRNA-inducible
IFN-
and interferon-stimulated cellular genes, 6-16 and 9-27, whose
transcription is mediated by interferon-stimulated response elements
(14). 6-16 transcription levels can be increased more than
100-fold by IFN-
but not significantly by IFN-
(23). Northern blot data for IFN-
and 6-16 gene expression are shown (Fig.
4B). Corresponding data for 9-27 (not shown) were qualitatively similar, although the overall transcription levels were lower. Endogenous levels of interferon in Daudi cells, reportedly low or
possibly absent (1), are consistent with our findings (Fig. 4B, track 1). Upon induction, however, as observed with D-HIT (Fig.
4A), both IFN-
and 6-16 RNA levels were enhanced, SB again being the
superior inducing agent (Fig. 4B; compare tracks 2 and 3). These data
alone, while revealing parallel transcriptional responses between
D-HIT, IFN-
, and 6-16, would not distinguish between induction as a
direct consequence of the chemical treatment, or in association with
expression of D-HIT or IFN-
, in these cells. Work by others shows
that TPA alone does not induce 6-16 transcription (7).
|
|
Expression of PKR in B cells in response to IFN-
or chemical
inducing agents.
Since Northern blot data showed comparable levels
of p68 transcripts in Daudi cell lines of various sensitivities (data
not shown), we examined whether varying control over translation might have been influencing interferon sensitivities. Expression of the
IFN-inducible, dsRNA-activated protein kinase, PKR, was thus examined
in the Daudi lines, using a monoclonal antibody to PKR (26).
In the first set of experiments (Fig.
5A), the levels of the endogenously
expressed protein were observed to be roughly the same in all of the
EBV-positive cell lines examined (Daudi/ATCC, Daudi/ICRF, and
Daudi/100K [tracks 3, 5, and 7, respectively]) and Raji cells (track
9), although below the level of detection in the EBV-negative Ramos
B-cell line (track 1). In interferon-treated cells, this level, as
anticipated, was increased (even in Ramos), except in the case of the
insensitive Daudi cell line, 100K (track 8). A similar pattern was
observed in Fig. 5B, the levels of protein in uninduced cells (tracks
3, 5, 7, and 9) being enhanced upon chemical induction with TPA and SB
(tracks 4, 6, and 10), except again in the interferon-insensitive 100K
line, where the levels remained essentially constant (track 8). Unlike
the findings with IFN-
, chemical induction had little or no effect
on PKR levels in Ramos cells (compare tracks 1 and 2 in Fig. 5A and B).
In EBV-carrying cells, TPA and SB seem to mimic the PKR stimulatory
effects of IFN-
, but whether or not this is the case in EBV-negative
cells needs to be further explored. Notably, the protein levels
themselves do not fully account for the different sensitivities to
IFN-
observed among the various cell lines. For example, the
virtually insensitive 100K line contains reasonable levels of protein.
|
PKR kinase activity.
As the biological activity of PKR depends
on its autophosphorylation and its ability to phosphorylate a subunit
of the protein initiation factor eIF-2
, phosphorylation of PKR in
Daudi, Raji, and Ramos cell lines was investigated. The protein kinase
from various cell extracts was immunoprecipitated with monoclonal
antibody 71/10 (26), and then autophosphorylation was
monitored in the presence of [
-32P]ATP
(18). Figure 5C shows data for radiolabelled proteins derived from untreated Ramos, Daudi/ATCC, Daudi/ICRF, Daudi/100K, and
Raji cells (tracks 1, 4, 7, 10, and 13, respectively). Other tracks
contain materials from the same cells after induction with IFN-
(tracks 2, 5, 8, 11, and 14) or treatment with TPA and SB (tracks 3, 6, 9, 12, and 15). The results show that the PKR protein is phosphorylated
in every case except in interferon-insensitive Daudi/100K or
EBV-negative Ramos cells. Further, whereas IFN-
treatment produces
enhanced levels of phosphorylated PKR in all EBV-positive cells (tracks
5, 8, and 14), the effect was greatest for the most sensitive
Daudi/ICRF line (track 8). Comparable results (compare with data in
Fig. 5B) were observed with chemically induced Daudi/ATCC and
Daudi/ICRF cells. But with Ramos and Raji cells, chemical induction was
only marginally effective as a means of stimulating PKR activity.
Notably, from previous studies (12), the levels of D-HIT in
Raji cells were little altered by chemical induction. With regard to
Daudi/100K, there is no evidence, from this experiment, of a
phosphorylated PKR in cells treated with either IFN-
or the chemical
reagents (Fig. 5C, tracks 11 and 12), although the protein is expressed
(Fig. 5A and B).
Comparison of IFN-
sensitivities in Raji cells transfected
with poly(I)-poly(C) or the D-HIT homolog. (i) Cell survival.
Cells were transfected with the different RNAs by using Effectene,
as described in Materials and Methods, in the presence or absence of
IFN-
. Ramos cells proved highly sensitive to the transfection
protocol in that only about 10% of cells survived conditions 1 (in the
absence of dsRNA) and fewer than this survived conditions 2. Thus, the
bulk of the experiment was carried out on Raji cells, where on average
on day 1, 46% cells had survived conditions 1 and 56% survived
conditions 2, compared with untreated controls. In the first sets of
experiments, proliferation of cells grown 5 days in the presence of
tritiated thymidine was assessed essentially as described previously
(5). The data under the two sets of conditions are shown in
Fig. 6. The control, taken as 100%, was
an average of the tritium count in Raji cells treated with IFN-
with
or without added Effectene. This control was adopted since it was
observed that Effectene reagent was actually less toxic to cells when
mixed with dsRNA. Under both sets of conditions, decrease in the
proliferating cell population was observed to correlate with the
quantity of added dsRNA, rather than to its composition, the most
significant increase (50%) being observed under conditions 2 with 16 µg of poly(I)-poly(C). With 4 µg, the synthetic dsRNA and the D-HIT
homolog gave comparable (40%) reductions.
|
(ii) Cell viability.
Cell viability was determined
microscopically after a total of 14 days (from the time of
transfection) by the trypan blue exclusion assay. In each case, the
numbers of cells from both experimental conditions were further
evaluated to determine the effects of 104 U of IFN-
on
survival, taking the average viable cell count of treated compared with
untreated cells (without added dsRNA) as 100%. Note that with the
control Daudi/ICRF cells, in the presence of 104 U of
IFN-
, virtually all the cells were killed within a few days. With
conditions 1, where comparable amounts of poly(I)-poly(C) and the D-HIT
homolog were used in the transfection mix, the survival rates at this
time were evaluated as 29 and 26%, respectively; with a fourfold
higher concentration of poly(I)-poly(C), this figure was 34%. Under
conditions 2, the corresponding figures by this technique were 27, 48, and 39%, respectively. No significance is placed on the precise
figures here, as mixtures of live and dead cells showed a tendency to
clump, reducing the count accuracy, especially when cell numbers were
decreasing. Comparison of these data with those for Raji cells (Fig.
2)
where at 14 days in the presence of 104 U of IFN-
,
60 to 70% of the cells were still alive
shows that cells had been
sensitized to the interferon by the addition of the dsRNAs, whether the
latter was of synthetic or EBV origin.
| |
DISCUSSION |
|---|
|
|
|---|
The high degree of secondary structure predicted and apparent in
an EBV transcript, designated D-HIT, and its variation in expression
levels among different EBV-carrying cell lines (12) stimulated us to investigate a possible association between this RNA
and the known differential sensitivities of certain EBV-positive B
lymphocytes to type I interferons (1, 2). D-HIT was found to
behave in the presence of RNases essentially as a dsRNA (Fig. 1), and
its constitutive expression was observed by Northern blots at low but
detectable levels, particularly in interferon-sensitive Daudi cells
(Fig. 3 and 4A; Table 1), suggesting that it might be an effector of
interferon pathways responsive to dsRNAs. Notably, interferon
sensitivities in non-chemically induced cells (Fig. 2) appeared to
parallel the endogenous levels of expression of D-HIT. This viral
transcript can be expressed at remarkably high levels when certain
Daudi lines, but not all other EBV-containing B-cell lines
investigated, are chemically induced. In Daudi cells, the
transcriptional expression of two interferon-sensitive human cellular
genes, 6-16 and 9-27, and to a much lesser extent that of the IFN-
gene itself, were also shown to be up-regulated following treatment
with TPA or SB (Fig. 4B).
Parental and mutant Daudi cells, with different sensitivities to
IFN-
, show no apparent difference in RNase L and 2,5-A synthetase activities (41). We thus explored D-HIT expression as it
might affect the other major interferon pathway, that involving the cellular protein kinase PKR, which regulates the transcriptional and
translational machinery of the cell. PKR is activated by a mechanism
that involves dsRNA binding in a sequence-independent manner
(32). In a series of experiments, typified by data shown in
Fig. 5, using two different primary Daudi cell lines, a mutant (100K)
from one of these, and as controls the relatively IFN-
insensitive
line Raji and the EBV-negative line Ramos, we compared protein levels
and autophosphorylation of PKR in cells treated either with IFN-
or
with TPA and SB. PKR protein levels were found to be essentially
indistinguishable among the IFN-sensitive lines (compare Fig. 5A and
B), with the chemical inducing agents mimicking the effects of
interferon in their ability to up-regulate expression. (Neither reagent
had much effect, however, on PKR levels in the Daudi
interferon-insensitive mutant line, 100K.) We observed little
difference in endogenous PKR levels among Raji, all Daudi, and Ramos
cells. In assays investigating the kinase activity of PKR (Fig. 5C),
the overall levels of phosphorylated PKR were considerably increased
when inducing agents (IFN-
; TPA and SB) were added to the cells,
with the chemical inducing agents again mimicking the action of
interferon in Daudi, but not in Raji, cells. (In the case of 100K, no
kinase activity was observed, although a 68-kDa-migrating protein is
clearly present in these cells [Fig. 5A and B], suggesting that an
inhibitor of phosphorylation may have been coimmunoprecipitated
together with PKR in this case, or alternatively, the protein was
already phosphorylated.) Our data suggest that D-HIT, acting as a
dsRNA, directly stimulates the activity of PKR. They support the
supposition that D-HIT per se, and not the chemical inducing agents, is
responsible for the observed effects; that is, whereas IFN-
stimulates the expression of PKR in the EBV-negative cell line Ramos,
this is not observed to be the case when TPA and SB are used (Fig. 5).
To examine this argument further, poly(I)-poly(C) dsRNA or an in
vitro-transcribed homolog of D-HIT was added to the in vitro PKR kinase
assay. Here, using comparable amounts of material, we found both
poly(I)-poly(C) and the viral transcript to stimulate
autophosphorylation of PKR. Increasing the concentration of the latter
10-fold nullified this effect, as observed earlier for poly(I)-poly(C)
(11) and other potentially double-stranded RNAs (6,
35).
Although B cells often prove problematic in transfection experiments,
they were chosen for the next set of experiments as the most
appropriate model for examining the effect of ds-RNA, including D-HIT,
on cell proliferation. The poly(I)-poly(C) and D-HIT RNAs were
transfected directly into Raji cells and proliferation was examined by
two assays, as described elsewhere (5). One of these used
tritiated thymidine, measuring radioactive uptake over a 5-day period,
7 days after introduction of the RNAs into in vitro cultures of Raji
cells in the presence of 104 U of IFN-
. In the absence
of added dsRNA, this technique had identified no differences over time
(4 and 6 days) in Raji cells treated with various concentrations of
IFN-
compared with untreated Raji or other B-cells (5).
As shown in Fig. 6, however, when Raji cells were transfected with
either the synthetic polymer or the D-HIT homolog, the number of
proliferating cells was reduced in the presence of IFN-
, in a manner
that corresponded to the amount of exogenous RNA added rather than to
the nature of the RNA, consistent with other studies (32).
Our data showed a 40 to 50% reduction in tritium uptake in the
presence of 16 µg of poly(I)-poly(C) and 22 to 40% (depending on
conditions) reduction in assays using 4 µg of either this RNA or the
D-HIT homolog. Further work to optimize these conditions might increase
these levels of sensitivity. Notably, as suggested elsewhere
(29), it may prove advantageous to increase the RNA
concentrations. In the second assay, cell survival in the presence of
104 U of IFN-
was measured. Where previous data (Fig. 2)
showed that after 14 days, about 70% of Raji cells had survived in the absence of added exogenous RNA, this figure was reduced to values ranging between 26 to 48% when the dsRNAs were added (Fig. 6). Again,
these experiments clearly indicate that D-HIT can mimic poly(I)-poly(C)
in sensitizing cells to the effects of interferon. In future, it may
prove advantageous to generate a library of EBV clones from Daudi cells
that will allow us to isolate D-HIT per se, since the viral gene
sequence in these cells (12) has a small change relative to
that used in the current experiments, which conceivably can influence
the stability of the dsRNA-like RNA and thus its overall effect on cells.
Throughout our investigations, we observed variation between the two
parental Daudi cell lines (ATCC and ICRF), both with regard to their
sensitivity to IFN-
and with regard to their endogenous and
inducible levels of D-HIT, growth habits, and even responses to
antibodies (13). These differences, which probably reflect
alterations that occurred at different times in the development and
treatment of the BL (24), have proved useful here in further allowing correlations between interferon response and D-HIT expression levels to be made. For Daudi/ICRF and to a lesser extent Daudi/ATCC cells, the enhanced sensitivity to IFN-
may be a consequence of the
fact that they contain detectable (although different) levels of
endogenous D-HIT. This suggestion is substantiated by the data shown in
Fig. 2, 3, and 4A and is supported by those for another
interferon-sensitive BL line, P3HR1 (2), which also
expresses detectable endogenous levels of this transcript. These
findings (summarized in Table 1) further indicate a correlation between
endogenous D-HIT expression and the relative interferon sensitivities
observed in EBV-carrying B-cell lines (Fig. 2).
The viral function EBNA2, shown to activate transcription of at least
one other viral protein (16), has been invoked as conferring
interferon resistance to cells (3). In the two most interferon sensitive EBV lines assessed, Daudi and P3HR1, deletions remove the gene for EBNA2 (20). The EBNA2 function is silent in most EBV-associated tumors, and yet interferon has proved
disappointing as a therapeutic agent. We postulated that another viral
(or host) function, expressed in cell lines but presumably largely
silent in tumors, may be relevant in understanding interferon
responsiveness. Our data suggest a direct role for the EBV transcript
D-HIT (or its homolog in other cells) in IFN-
induction or
activities associated with cellular responses to interferon, or both,
that is, in sensitizing cells to interferon. An alternative role can be
suggested for EBNA2. That is, were it acting as a down-regulator of
transcriptional expression of the D-HIT promoter, then sensitivity
would be lost. This has not been explored. Another, obvious mechanism
for down-regulation of transcriptional expression would involve
epigenetic events, notably down-regulation by methylation. Table
2 presents data which show that over the
promoter/transcriptional initiation region of D-HIT, the numbers of CpG
and GpC dinucleotides are both high and comparable. This strongly
suggests that the promoter behaves as a CpG island, many of which act
as methylation hot spots (8) and control transcriptional
expression.
|
The normal function of D-HIT and its homologs in EBV-infected cells and associated tumors has not been defined, although the fact that its promoter may incorporate a lytic origin of replication (12, 15) suggests a regulatory role in the viral life cycle. In most infected cells and EBV-associated tumors, however, little or no lytic replication is observed, although in some cell lines it can be stimulated by TPA and SB. Levels of endogenous expression of D-HIT, or homologs, in tumors are very low, detectable only by reverse transcription-PCR methods (our unpublished observations). The significance of the present findings, where D-HIT may act to sensitize cells to interferon, suggests that understanding the regulation of this transcript could have practical consequences for growth control of EBV-associated malignancies by this cytokine. It is predicted that the viral transcript should be relatively insensitive to the 2,5-A dependent RNase, which chiefly acts on single-stranded RNA (30), and in stimulating the autophosphorylation of PKR (Fig. 5D), D-HIT may offer a natural, valuable molecule for studying interferon action, as proposed (Fig. 7).
|
| |
ACKNOWLEDGMENTS |
|---|
We acknowledge support provided by the Cancer Research Campaign, United Kingdom (to Y.G.), the European Community (contract 1C18-CT96-0132, to S.A.X.) and The Leverhulme Trust (to B.E.G.) for this work.
We thank I. M. Kerr for critical comments on the manuscript and Daniel Holleyman for help with the figures.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Viral Oncology Unit, Division of Medicine, Imperial College of Medicine, St. Mary's site, Norfolk Place, London W2 1PG, United Kingdom. Phone: 44 171 594 3670. Fax: 44 171 402 1037. E-mail: bgriffin{at}ic.ac.uk.
Present address: Cancer Research Institute, CAMS, Beijing 100021, People's Republic of China.
Present address: Viral Oncology Unit, Division of Medicine,
Imperial College of Medicine, London W2 1PG, United Kingdom.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Adams, A.,
B. Lidin,
H. Strander, and K. Cantell.
1975.
Spontaneous interferon production and Epstein-Barr virus antigen expression in human lymphoid cell lines.
J. Gen. Virol.
28:219-223 |
| 2. |
Adams, A.,
H. Strander, and K. Cantell.
1975.
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
J. Gen. Virol.
28:207-217 |
| 3. | Åman, P., and A. von Gabain. 1990. An Epstein-Barr virus immortalization associated gene segment interferes specifically with the IFN-induced antiproliferative response in human B-lymphoid cell lines. EMBO J. 9:147-152[Medline]. |
| 4. |
Arrand, J. R.,
L. Rymo,
J. E. Walsh,
E. Björck,
T. Lindahl, and B. E. Griffin.
1981.
Molecular cloning of the complete Epstein-Barr virus genome as a set of overlapping restriction endonuclease fragments.
Nucleic Acids Res.
9:2999-3014 |
| 5. |
Blomhoff, H. K.,
C. Davies,
E. Ruud,
S. Funderud, and T. Godal.
1985.
Distinct effects of interferon on human B-lymphocyte precursor cell lines.
Scand. J. Immunol.
22:611-617[Medline].
|
| 6. |
Chu, W.-M.,
R. Ballard,
B. W. Carpick,
B. R. G. Williams, and C. W. Schmid.
1998.
Potential Alu function: regulation of the activity of double-stranded RNA-activated kinase PKR.
Mol. Cell. Biol.
18:58-68 |
| 7. | Clemens, M. J., V. J. Tilleray, R. James, and D. R. Gewert. 1988. Relationship of cellular oncogene expression in interferon-treated cells. Implications for the regulation of protein synthesis and the antiviral state. J. Cell. Biochem. 38:251-259[Medline]. |
| 8. | Cross, S. H., and A. P. Bird. 1995. CpG islands and genes. Curr. Opin. Genet. Dev. 5:309-314[Medline]. |
| 9. |
Dron, M., and M. G. Tovey.
1983.
Isolation of Daudi cells with reduced sensitivity to interferon. I. Characterization.
J. Gen. Virol.
64:2641-2647 |
| 10. |
Elia, A.,
K. G. Laing,
A. Schofield,
V. J. Tilleray, and M. J. Clemens.
1996.
Regulation of the double-stranded RNA-dependent protein kinase PKR by RNAs encoded by a repeated sequence in the Epstein-Barr virus genome.
Nucleic Acids Res.
24:4471-4478 |
| 11. | Galabru, J., M. G. Katze, N. Robert, and A. G. Hovanessian. 1989. Autophosphorylation of the protein kinase dependent on double-stranded RNA. Euro. J. Biochem. 178:581-589[Medline]. |
| 12. | Gao, Y., P. R. Smith, L. Karran, Q. L. Lu, and B. E. Griffin. 1997. Induction of an exceptionally high-level, nontranslated, Epstein-Barr virus-encoded polyadenylated transcript in the Burkitt's lymphoma line Daudi. J. Virol. 71:84-94[Abstract]. |
| 13. | Gao, Y. 1998. Properties of the highly inducible EBV IR4 transcript in Daudi cells and possible association with interferon sensitivity. Ph.D. thesis. University of London, London, England. |
| 14. | Guille, M. J., C. D. Laxton, M. N. Rutherford, B. R. G. Williams, and I. M. Kerr. 1994. Functional differences in the promoters of the interferon-inducible (2'-5')A oligoadenylate synthetase and 6-16 genes in interferon-resistant Daudi cells. Eur. J. Biochem. 219:547-553[Medline]. |
| 15. | Hammerschmidt, W., and B. Sugden. 1988. Identification and characterization of oriLyt, a lytic origin of DNA replication. Cell 55:427-433[Medline]. |
| 16. | Harada, S., and E. Kieff. 1997. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J. Virol. 71:6611-6618[Abstract]. |
| 17. | Hitt, M. M., M. Allday, T. Hara, L. Karran, M. D. Jones, P. Busson, T. Tursz, I. Ernberg, and B. E. Griffin. 1989. EBV gene expression in an NPC-related tumour. EMBO J. 8:2639-2651[Medline]. |
| 18. | Hovanessian, A. G., J. Galabru, E. Meurs, C. Buffet-Janvresse, J. Svab, and N. Robert. 1987. Rapid decrease in the double-stranded RNA-dependent protein kinase during virus infections. Virology 159:126-136[Medline]. |
| 19. | Hunter, T., T. Hunt, and R. J. Jackson. 1975. The characteristics of inhibition of protein synthesis by double-stranded ribonucleic acid in reticulocyte lysates. J. Biol. Chem. 25:409-417. |
| 20. | Jones, M. D., L. Foster, T. Sheddy, and B. E. Griffin. 1984. The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR1) of the virus. EMBO J. 3:813-821[Medline]. |
| 21. |
Kanda, K.,
T. Decker,
P. Åman,
M. Wahlstrõm,
A. von Gagain, and B. Kallin.
1992.
The EBNA2-related resistance towards alpha interferon (IFN- ) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3.
Mol. Cell. Biol.
12:4930-4936 |
| 22. |
Karran, L.,
Y. Gao,
P. R. Smith, and B. E. Griffin.
1992.
Expression of a family of complementary-strand transcripts in Epstein-Barr virus-infected cells.
Proc. Natl. Acad. Sci. USA
89:8058-8062 |
| 23. | Kelly, J. M., C. S. Gilbert, G. R. Stark, and I. M. Kerr. 1985. Differential regulation of interferon-induced mRNAs and c-myc mRNA by alpha- and gamma-interferons. Eur. J. Biochem. 153:367-371[Medline]. |
| 23a. | Kerr, I. M. Personal communication. |
| 24. |
Klein, E.,
G. Klein,
J. S. Nadkarni,
J. J. Nadkarni,
H. Wigzell, and P. Clifford.
1968.
Surface IgM specificity on cells derived from a Burkitt lymphoma.
Cancer Res.
28:1300-1310 |
| 25. |
Kumar, A.,
J. Haque,
L. Lacoste,
J. Hisott, and B. R. Williams.
1994.
Double-stranded RNA-dependent protein kinase activates transcription factor NF- B by phosphorylating I B.
Proc. Natl. Acad. Sci. USA
91:6288-6292 |
| 26. |
Laurent, A. G.,
B. Krust,
J. Balabru,
J. Svab, and A. G. Hovanessian.
1985.
Monoclonal antibodies to an interferon-induced Mr 68,000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells.
Proc. Natl. Acad. Sci. USA
82:4341-4345 |
| 27. |
Laux, G.,
U. K. Freese, and G. W. Bornkamm.
1985.
Structure and evolution of two related transcription units of Epstein-Barr virus carrying small tandem repeats.
J. Virol.
56:987-995 |
| 28. |
Lengyel, P.
1993.
Tumor-suppressor genes: news about the interferon connection.
Proc. Natl. Acad. Sci. USA
90:5893-5895 |
| 29. | Luvrukhina, L. A., and F. I. Ershov. 1985. Antiproliferative effect of interferon inducers. Vopr. Virusol. 30:446-449[Medline]. |
| 30. |
Maran, A.,
R. K. Maitra,
A. Kumar,
B. Dong,
X. Wei,
G. Li,
B. R. G. Williams,
R. F. Torrence, and R. H. Silverman.
1994.
Blockage of NF- B signalling by selective ablation of an mRNA target by 2-5A antisense chimeras.
Science
265:789-792 |
| 31. |
McMahon, M.,
G. R. Stark, and I. M. Kerr.
1986.
Interferon-induced gene expression in wild-type and interferon-resistant human lymphoblastoid (Daudi) cells.
J. Virol.
57:362-366 |
| 32. | Nanduri, S., B. W. Carpick, Y. Yang, B. R. G. Williams, and J. Qin. 1998. Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-medicated activation. EMBO J. 17:5458-5465[Medline]. |
| 33. | Offermann, M. K., J. Zimring, K. H. Mellits, M. K. Hagan, R. Shaw, R. M. Medford, M. B. Mathews, S. Goodbourn, and R. Jagus. 1995. Activation of the double-stranded RNA-activated protein kinase and induction of vascular cell adhesion molecule-1 by poly(I):poly(C) in endothelial cells. Eur. J. Biochem. 232:28-36[Medline]. |
| 34. | Parker, B. D., A. Bankier, S. Satchwell, B. Barrell, and P. J. Farrell. 1990. Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology 179:339-346[Medline]. |
| 35. | Pe'ery, T., and M. B. Mathews. 1997. Synthesis and purification of single-stranded RNA for use in experiments with PKR and in cell-free translation systems. Methods 11:371-381[Medline]. |
| 36. | Polack, A., D. Eick, E. Koch, and G. W. Bornkamm. 1987. Truncation does not abrogate transcriptional downregulation of the c-myc gene by sodium butyrate in Burkitt's lymphoma cells. EMBO J. 6:2959-2964[Medline]. |
| 37. |
Raveh, T.,
A. G. Hovanessian,
E. F. Meuro,
N. Sonenberg, and M. J. Clemens.
1996.
Double-stranded RNA-dependent protein kinase mediates c-myc suppression induced by type I interferons.
J. Biol. Chem.
271:25479-25484 |
| 38. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed., p. 10.27-10.37. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 39. | Sen, G. C. 1991. Transcriptional regulation of interferon-inducible genes, p. 349-374. In P. Cohen, and J. G. Foulkes (ed.), The hormonal control of gene transcription. Elsevier, Amsterdam, The Netherlands. |
| 40. |
Sharp, T. V.,
M. Schwemmle,
I. Jeffrey,
K. Laing,
H. Mellor,
C. Proud,
K. Hilse, and M. J. Clemens.
1993.
Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA.
Nucleic Acids Res.
21:4483-4491 |
| 41. | Silverman, R. H., D. Watling, F. R. Balkwill, J. Trowsdale, and I. M. Kerr. 1982. The ppp(A2'p)nA and protein kinase systems in wild type and interferon-resistant Daudi cells. Eur. J. Biochem. 126:333-341[Medline]. |
| 42. | Tiwari, R. K., J. Kusari, and G. C. Sen. 1987. Functional equivalents of interferon-mediated signals needed for induction of an mRNA can be generated by double-stranded RNA and growth factors. EMBO J. 6:3373-3378[Medline]. |
| 43. |
Zuker, M.
1989.
On finding all suboptimal foldings of an mRNA molecule.
Science
244:48-52 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. |
|---|